Virtu Financial LLC Nymox Pharmaceutical Corp Transaction History

Virtu Financial LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$0.19 - $0.49 $1,340 - $3,455	7,053 Added 52.93%	20,377 $4,000
Q1 2023 May 01, 2023	SELL	$0.33 - $0.5 $2,086 - $3,161	-6,322 Reduced 32.18%	13,324 $5,000
Q4 2022 Feb 15, 2023	BUY	$0.28 - $0.74 $5,500 - $14,538	19,646 New	19,646 $6,000
Q2 2021 Sep 17, 2021	SELL	$1.46 - $2.48 $18,232 - $30,970	-12,488 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$2.22 - $3.39 $27,723 - $42,334	12,488 New	12,488 $28,000
Q4 2020 Feb 24, 2021	SELL	$1.84 - $2.83 $21,452 - $32,994	-11,659 Closed	0 $0
Q3 2020 Dec 11, 2020	SELL	$2.3 - $3.66 $37,906 - $60,320	-16,481 Reduced 58.57%	11,659 $29,000
Q2 2020 Aug 07, 2020	SELL	$2.1 - $4.6 $422 - $924	-201 Reduced 0.71%	28,140 $100,000
Q4 2019 Feb 04, 2020	BUY	$1.73 - $2.42 $49,029 - $68,585	28,341 New	28,341 $62,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.